Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: Preliminary results of a Vanderbilt trial

David H. Johnson, Russell DeVore, F. Anthony Greco, Jay Walls, Melodie Thomas, Kenneth R. Hande, John D. Hainsworth

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Twenty-eight patients with unresectable, metastatic non-small cell lung cancer (NSCLC) were treated with carboplatin/oral etoposide. Carboplatin was administered intravenously on day 1 at a dose of 300 mg/m2 (12 patients) or 350 mg/m2 (16 patients); oral etoposide was administered at a dose of 50 mg/m2/d for 21 consecutive days. Treatment was repeated every 28 days. Patient characteristics included male:female ratio of 23: 5, median age of 60 years, median Eastern Cooperative Oncology Group performance status of 1, weight loss of 5% or more in seven patients; stage IIIB disease in two patients and stage IV in 26. Twenty-five patients were evaluable for response and seven (28%) achieved a partial response (95% confidence interval, 14% to 48%). Median duration of response was 3+ months (range, 2+ to 6+) and median survival was 4+ months (range, 1 + to 10+). Myelosuppression was the predominate toxicity; leukocyte and platelet nadirs occurred between days 22 and 29, with median counts of 2,900/μL and 172,000/ μL respectively. The median interval between the start of cycle 1 and the start of cycle 2 was 33 days (range, 26 to 42). Carboplatin/oral etoposide is a moderately active regimen against advanced NSCLC that can be administered in an outpatient setting with manageable toxicity. Its impact on survival remains to be determined.

Original languageEnglish (US)
Pages (from-to)50-56
Number of pages7
JournalSeminars in Oncology
Volume19
Issue number1 SUPPL. 2
Publication statusPublished - 1992

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Johnson, D. H., DeVore, R., Greco, F. A., Walls, J., Thomas, M., Hande, K. R., & Hainsworth, J. D. (1992). Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: Preliminary results of a Vanderbilt trial. Seminars in Oncology, 19(1 SUPPL. 2), 50-56.